- Adding induction chemotherapy (IC) before concurrent chemoradiotherapy (CCRT) improves DFS, driven by distant metastasis-free survival (DMFS) in locoregionally advanced nasopharyngeal carcinoma (NPC).
- There was no effect on locoregional relapse-free survival (LRRFS) or OS.
Why this matters
- This study supports the findings from a prior follow-up at 3 years.
- IC+CCRT was associated with improved 5-year DFS (73.4% vs 63.1%; HR, 0.68; P=.01) and DMFS (82.8% vs 73.1%; HR, 0.65; P=.03) compared with CCRT alone in multivariate analysis.
- Results were not statistically significant for OS (80.8% vs 76.8%; P=.06) or LRRFS (87.9% vs 85.0%; P=.21).
- IC+CCRT was associated with higher incidence of grade 3-4 adverse events compared with CCRT alone (66.3% vs 49.1%; P<.001 although a lower rate of eye damage was observed vs p=".029).</li">
- 238 patients who received IC (cisplatin/fluorouracil) followed by CCRT (cisplatin/RT) and 238 who received CCRT alone were included.
- Funding: Sun Yat-sen University; Guangdong Public Welfare Research and Capacity Building Projects; National Key Research and Development Program of China; Guangzhou Science and Technology Planning Project-Production and Research Collaborative Innovation Major Project; National Natural Science Foundation of China.
- Open-label trial.
- Not all patients received intensity-modulated RT.